Seven Eight Capital’s 10x Genomics TXG Stock Holding History

Seven Eight Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-35,924	Closed	-$699K	–	955
2024 Q2	$699K	Sell	35,924 -63,954	-64%	-$1.67M	0.07%	452
2024 Q1	$3.75M	Buy	+99,878	New	+$4.39M	0.39%	66
2023 Q4	–	Sell	-10,161	Closed	-$419K	–	842
2023 Q3	$419K	Buy	+10,161	New	+$529K	0.05%	429
2022 Q4	–	Sell	-19,061	Closed	-$543K	–	640
2022 Q3	$543K	Buy	+19,061	New	+$726K	0.11%	261
2021 Q2	–	Sell	-1,500	Closed	-$212K	–	711
2021 Q1	$212K	Hold	1,500	–	–	0.05%	368
2020 Q4	$212K	Sell	1,500 -1,700	-53%	-$247K	0.05%	373
2020 Q3	$399K	Buy	+3,200	New	+$336K	0.09%	399
2020 Q2	–	Sell	-5,500	Closed	-$343K	–	562
2020 Q1	$343K	Buy	+5,500	New	+$429K	0.09%	285

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Seven Eight Capital's TXG Position: Q3 2024 in Review

Seven Eight Capital sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 35,924 shares — an estimated $699K sold.

Seven Eight Capital first reported a position in TXG in Q1 2020 and held it in 8 quarters. The position peaked at $3.75M in Q1 2024. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

Seven Eight Capital reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
Seven Eight Capital sold 35,924 10x Genomics shares in Q3 2024, an estimated $699K.
Seven Eight Capital first reported a position in 10x Genomics in Q1 2020 and held it in 8 quarters.
Seven Eight Capital's 10x Genomics position peaked at $3.75M in Q1 2024.
266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.